



SHARGEL & YU'S

# APPLIED BIOPHARMACEUTICS AND PHARMACOKINETICS

SEVENTH EDITION

LEON SHARGEL  
ANDREW B.C. YU

Mc  
Graw  
Hill  
Education

# Applied Biopharmaceutics & Pharmacokinetics

### **Notice**

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

# Applied Biopharmaceutics & Pharmacokinetics

Seventh Edition

## EDITORS

**Leon Shargel, PhD, RPh**

*Applied Biopharmaceutics, LLC  
Raleigh, North Carolina  
Affiliate Professor, School of Pharmacy  
Virginia Commonwealth University, Richmond, Virginia  
Adjunct Associate Professor, School of Pharmacy  
University of Maryland, Baltimore, Maryland*

**Andrew B.C. Yu, PhD, RPh**

*Registered Pharmacist  
Gaithersburg, Maryland  
Formerly Associate Professor of Pharmaceutics  
Albany College of Pharmacy  
Albany, New York  
Formerly CDER, FDA  
Silver Spring, Maryland*



New York Chicago San Francisco Athens London Madrid Mexico City  
Milan New Delhi Singapore Sydney Toronto

Copyright © 2016 by McGraw-Hill Education. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher, with the exception that the program listings may be entered, stored, and executed in a computer system, but they may not be reproduced for publication.

ISBN: 978-0-07-182964-9

MHID: 0-07-182964-4

The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-183093-5,  
MHID: 0-07-183093-6.

eBook conversion by codeMantra  
Version 1.0

All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps.

McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a representative, please visit the Contact Us page at [www.mhprofessional.com](http://www.mhprofessional.com).

Previous editions copyright © 2012 by The McGraw-Hill Companies, Inc.; © 2005, 1999, 1993 by Appleton & Lange; © 1985, 1980 by Appleton-Century-Crofts.

#### TERMS OF USE

This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill Education's prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.

THE WORK IS PROVIDED "AS IS." MCGRAW-HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.

# Contents

Contributors xi  
Preface xv  
Preface to First Edition xvii

## 1. Introduction to Biopharmaceutics and Pharmacokinetics 1

Drug Product Performance 1  
Biopharmaceutics 1  
Pharmacokinetics 4  
Pharmacodynamics 4  
Clinical Pharmacokinetics 5  
Practical Focus 8  
Pharmacodynamics 10  
Drug Exposure and Drug Response 10  
Toxicokinetics and Clinical Toxicology 10  
Measurement of Drug Concentrations 11  
Basic Pharmacokinetics and Pharmacokinetic Models 15  
Chapter Summary 21  
Learning Questions 22  
Answers 23  
References 25  
Bibliography 25

## 2. Mathematical Fundamentals in Pharmacokinetics 27

Calculus 27  
Graphs 29  
Practice Problem 31  
Mathematical Expressions and Units 33  
Units for Expressing Blood Concentrations 34  
Measurement and Use of Significant Figures 34  
Practice Problem 35  
Practice Problem 36  
Rates and Orders of Processes 40  
Chapter Summary 42  
Learning Questions 43  
Answers 46  
References 50

## 3. Biostatistics 51

Variables 51  
Types of Data (Nonparametric Versus Parametric) 51  
Distributions 52

Measures of Central Tendency 53  
Measures of Variability 54  
Hypothesis Testing 56  
Statistically Versus Clinically Significant Differences 58  
Statistical Inference Techniques in Hypothesis Testing for Parametric Data 59  
Goodness of Fit 63  
Statistical Inference Techniques for Hypothesis Testing With Nonparametric Data 63  
Controlled Versus Noncontrolled Studies 66  
Blinding 66  
Confounding 66  
Validity 67  
Bioequivalence Studies 68  
Evaluation of Risk for Clinical Studies 68  
Chapter Summary 70  
Learning Questions 70  
Answers 72  
References 73

## 4. One-Compartment Open Model: Intravenous Bolus Administration 75

Elimination Rate Constant 76  
Apparent Volume of Distribution 77  
Clearance 80  
Clinical Application 85  
Calculation of  $k$  From Urinary Excretion Data 86  
Practice Problem 87  
Practice Problem 88  
Clinical Application 89  
Chapter Summary 90  
Learning Questions 90  
Answers 92  
Reference 96  
Bibliography 96

## 5. Multicompartment Models: Intravenous Bolus Administration 97

Two-Compartment Open Model 100  
Clinical Application 105

Practice Problem	107
Practical Focus	107
Practice Problem	110
Practical Focus	113
Three-Compartment Open Model	114
Clinical Application	115
Clinical Application	116
Determination of Compartment Models	116
Practical Focus	117
Clinical Application	118
Practical Problem	120
Clinical Application	121
Practical Application	121
Clinical Application	122
Chapter Summary	123
Learning Questions	124
Answers	126
References	128
Bibliography	129

## 6. Intravenous Infusion 131

One-Compartment Model Drugs	131
Infusion Method for Calculating Patient Elimination	
Half-Life	135
Loading Dose Plus IV Infusion—One-Compartment Model	136
Practice Problems	138
Estimation of Drug Clearance and $V_D$ From Infusion Data	140
Intravenous Infusion of Two-Compartment Model Drugs	141
Practical Focus	142
Chapter Summary	144
Learning Questions	144
Answers	146
Reference	148
Bibliography	148

## 7. Drug Elimination, Clearance, and Renal Clearance 149

Drug Elimination	149
Drug Clearance	150
Clearance Models	152
The Kidney	157
Clinical Application	162
Practice Problems	163
Renal Clearance	163
Determination of Renal Clearance	168
Practice Problem	169
Practice Problem	169
Relationship of Clearance to Elimination Half-Life and Volume of Distribution	170
Chapter Summary	171
Learning Questions	171
Answers	172

References	175
Bibliography	175

## 8. Pharmacokinetics of Oral

### Absorption 177

Introduction	177
Basic Principles of Physiologically Based Absorption Kinetics (Bottom-Up Approach)	178
Absorption Kinetics (The Top-Down Approach)	182
Pharmacokinetics of Drug Absorption	182
Significance of Absorption Rate Constants	184
Zero-Order Absorption Model	184
Clinical Application—Transdermal Drug Delivery	185
First-Order Absorption Model	185
Practice Problem	191
Chapter Summary	199
Answers	200
Application Questions	202
References	203
Bibliography	204

## 9. Multiple-Dosage Regimens 205

Drug Accumulation	205
Clinical Example	209
Repetitive Intravenous Injections	210
Intermittent Intravenous Infusion	214
Clinical Example	216
Estimation of $k$ and $V_D$ of Aminoglycosides in Clinical Situations	217
Multiple-Oral-Dose Regimen	218
Loading Dose	219
Dosage Regimen Schedules	220
Clinical Example	222
Practice Problems	222
Chapter Summary	224
Learning Questions	225
Answers	226
References	228
Bibliography	228

## 10. Nonlinear Pharmacokinetics 229

Saturable Enzymatic Elimination Processes	231
Practice Problem	232
Practice Problem	233
Drug Elimination by Capacity-Limited Pharmacokinetics: One-Compartment Model, IV Bolus Injection	233
Practice Problems	235
Clinical Focus	242
Clinical Focus	243
Drugs Distributed as One-Compartment Model and Eliminated by Nonlinear Pharmacokinetics	243

Clinical Focus 244  
 Chronopharmacokinetics and Time-Dependent Pharmacokinetics 245  
 Clinical Focus 247  
 Bioavailability of Drugs That Follow Nonlinear Pharmacokinetics 247  
 Nonlinear Pharmacokinetics Due to Drug–Protein Binding 248  
 Potential Reasons for Unsuspected Nonlinearity 251  
 Dose-Dependent Pharmacokinetics 252  
 Clinical Example 253  
 Chapter Summary 254  
 Learning Questions 254  
 Answers 255  
 References 257  
 Bibliography 258

## 11. Physiologic Drug Distribution and Protein Binding 259

Physiologic Factors of Distribution 259  
 Clinical Focus 267  
 Apparent Volume Distribution 267  
 Practice Problem 270  
 Protein Binding of Drugs 273  
 Clinical Examples 275  
 Effect of Protein Binding on the Apparent Volume of Distribution 276  
 Practice Problem 279  
 Clinical Example 280  
 Relationship of Plasma Drug–Protein Binding to Distribution and Elimination 281  
 Clinical Examples 282  
 Clinical Example 284  
 Determinants of Protein Binding 285  
 Clinical Example 285  
 Kinetics of Protein Binding 286  
 Practical Focus 287  
 Determination of Binding Constants and Binding Sites by Graphic Methods 287  
 Clinical Significance of Drug–Protein Binding 290  
 Clinical Example 299  
 Clinical Example 300  
 Modeling Drug Distribution 301  
 Chapter Summary 302  
 Learning Questions 303  
 Answers 304  
 References 306  
 Bibliography 307

## 12. Drug Elimination and Hepatic Clearance 309

Route of Drug Administration and Extrahepatic Drug Metabolism 309

Practical Focus 311  
 Hepatic Clearance 311  
 Extrahepatic Metabolism 312  
 Enzyme Kinetics—Michaelis–Menten Equation 313  
 Clinical Example 317  
 Practice Problem 319  
 Anatomy and Physiology of the Liver 321  
 Hepatic Enzymes Involved in the Biotransformation of Drugs 323  
 Drug Biotransformation Reactions 325  
 Pathways of Drug Biotransformation 326  
 Drug Interaction Example 331  
 Clinical Example 338  
 First-Pass Effects 338  
 Hepatic Clearance of a Protein-Bound Drug: Restrictive and Nonrestrictive Clearance From Binding 344  
 Biliary Excretion of Drugs 346  
 Clinical Example 348  
 Role of Transporters on Hepatic Clearance and Bioavailability 348  
 Chapter Summary 350  
 Learning Questions 350  
 Answers 352  
 References 354  
 Bibliography 355

## 13. Pharmacogenetics and Drug Metabolism 357

Genetic Polymorphisms 358  
 Cytochrome P-450 Isozymes 361  
 Phase II Enzymes 366  
 Transporters 367  
 Chapter Summary 368  
 Glossary 369  
 Abbreviations 369  
 References 370

## 14. Physiologic Factors Related to Drug Absorption 373

Drug Absorption and Design of a Drug Product 373  
 Route of Drug Administration 374  
 Nature of Cell Membranes 377  
 Passage of Drugs Across Cell Membranes 378  
 Drug Interactions in the Gastrointestinal Tract 389  
 Oral Drug Absorption 390  
 Oral Drug Absorption During Drug Product Development 401  
 Methods for Studying Factors That Affect Drug Absorption 402  
 Effect of Disease States on Drug Absorption 405  
 Miscellaneous Routes of Drug Administration 407



Chapter Summary 408  
 Learning Questions 409  
 Answers to Questions 410  
 References 411  
 Bibliography 414

## 15. Biopharmaceutic Considerations in Drug Product Design and *In Vitro* Drug Product Performance 415

Biopharmaceutic Factors and Rationale for Drug Product Design 416  
 Rate-Limiting Steps in Drug Absorption 418  
 Physicochemical Properties of the Drug 420  
 Formulation Factors Affecting Drug Product Performance 423  
 Drug Product Performance, *In Vitro*: Dissolution and Drug Release Testing 425  
 Compendial Methods of Dissolution 429  
 Alternative Methods of Dissolution Testing 431  
 Dissolution Profile Comparisons 434  
 Meeting Dissolution Requirements 436  
 Problems of Variable Control in Dissolution Testing 437  
 Performance of Drug Products: *In Vitro*–*In Vivo* Correlation 437  
 Approaches to Establish Clinically Relevant Drug Product Specifications 441  
 Drug Product Stability 445  
 Considerations in the Design of a Drug Product 446  
 Drug Product Considerations 450  
 Clinical Example 456  
 Chapter Summary 461  
 Learning Questions 462  
 Answers 462  
 References 463  
 Bibliography 466

## 16. Drug Product Performance, *In Vivo*: Bioavailability and Bioequivalence 469

Drug Product Performance 469  
 Purpose of Bioavailability and Bioequivalence Studies 471  
 Relative and Absolute Availability 472  
 Practice Problem 474  
 Methods for Assessing Bioavailability and Bioequivalence 475  
*In Vivo* Measurement of Active Moiety or Moieties in Biological Fluids 475  
 Bioequivalence Studies Based on Pharmacodynamic Endpoints—*In Vivo* Pharmacodynamic (PD) Comparison 478  
 Bioequivalence Studies Based on Clinical Endpoints—Clinical Endpoint Study 479  
*In Vitro* Studies 481

Other Approaches Deemed Acceptable (by the FDA) 482  
 Bioequivalence Studies Based on Multiple Endpoints 482  
 Bioequivalence Studies 482  
 Design and Evaluation of Bioequivalence Studies 484  
 Study Designs 490  
 Crossover Study Designs 491  
 Clinical Example 496  
 Clinical Example 496  
 Pharmacokinetic Evaluation of the Data 497  
 The Partial AUC in Bioequivalence Analysis 498  
 Examples of Partial AUC Analyses 499  
 Bioequivalence Examples 500  
 Study Submission and Drug Review Process 502  
 Waivers of *In Vivo* Bioequivalence Studies (Biowaivers) 503  
 The Biopharmaceutics Classification System (BCS) 507  
 Generic Biologics (Biosimilar Drug Products) 510  
 Clinical Significance of Bioequivalence Studies 511  
 Special Concerns in Bioavailability and Bioequivalence Studies 512  
 Generic Substitution 514  
 Glossary 517  
 Chapter Summary 520  
 Learning Questions 520  
 Answers 525  
 References 526

## 17. Biopharmaceutical Aspects of the Active Pharmaceutical Ingredient and Pharmaceutical Equivalence 529

Introduction 529  
 Pharmaceutical Alternatives 533  
 Practice Problem 534  
 Bioequivalence of Drugs With Multiple Indications 536  
 Formulation and Manufacturing Process Changes 536  
 Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules 536  
 Changes to an Approved NDA or ANDA 537  
 The Future of Pharmaceutical Equivalence and Therapeutic Equivalence 538  
 Biosimilar Drug Products 539  
 Historical Perspective 540  
 Chapter Summary 541  
 Learning Questions 541  
 Answers 542  
 References 542

## 18. Impact of Biopharmaceuticals on Drug Product Quality and Clinical Efficacy 545

- Risks From Medicines 545
- Risk Assessment 546
- Drug Product Quality and Drug Product Performance 547
- Pharmaceutical Development 547
- Example of Quality Risk 550
- Excipient Effect on Drug Product Performance 553
- Practical Focus 554
- Quality Control and Quality Assurance 554
- Practical Focus 555
- Risk Management 557
- Scale-Up and Postapproval Changes (SUPAC) 558
- Practical Focus 561
- Product Quality Problems 561
- Postmarketing Surveillance 562
- Glossary 562
- Chapter Summary 563
- Learning Questions 564
- Answers 564
- References 565
- Bibliography 565

## 19. Modified-Release Drug Products and Drug Devices 567

- Modified-Release (MR) Drug Products and Conventional (Immediate-Release, IR) Drug Products 567
- Biopharmaceutical Factors 572
- Dosage Form Selection 575
- Advantages and Disadvantages of Extended-Release Products 575
- Kinetics of Extended-Release Dosage Forms 577
- Pharmacokinetic Simulation of Extended-Release Products 578
- Clinical Examples 580
- Types of Extended-Release Products 581
- Considerations in the Evaluation of Modified-Release Products 601
- Evaluation of Modified-Release Products 604
- Evaluation of *In Vivo* Bioavailability Data 606
- Chapter Summary 608
- Learning Questions 609
- References 609
- Bibliography 613

## 20. Targeted Drug Delivery Systems and Biotechnological Products 615

- Biotechnology 615
- Drug Carriers and Targeting 624
- Targeted Drug Delivery 627

- Pharmacokinetics of Biopharmaceuticals 630
- Bioequivalence of Biotechnology-Derived Drug Products 631
- Learning Questions 632
- Answers 632
- References 633
- Bibliography 633

## 21. Relationship Between Pharmacokinetics and Pharmacodynamics 635

- Pharmacokinetics and Pharmacodynamics 635
- Relationship of Dose to Pharmacologic Effect 640
- Relationship Between Dose and Duration of Activity ( $t_{\text{eff}}$ ), Single IV Bolus Injection 643
- Practice Problem 643
- Effect of Both Dose and Elimination Half-Life on the Duration of Activity 643
- Effect of Elimination Half-Life on Duration of Activity 644
- Substance Abuse Potential 644
- Drug Tolerance and Physical Dependency 645
- Hypersensitivity and Adverse Response 646
- Chapter Summary 673
- Learning Questions 674
- Answers 677
- References 678

## 22. Application of Pharmacokinetics to Clinical Situations 681

- Medication Therapy Management 681
- Individualization of Drug Dosage Regimens 682
- Therapeutic Drug Monitoring 683
- Clinical Example 690
- Clinical Example 692
- Design of Dosage Regimens 692
- Conversion From Intravenous Infusion to Oral Dosing 694
- Determination of Dose 696
- Practice Problems 696
- Effect of Changing Dose and Dosing Interval on  $C_{\text{max}}^{\infty}$ ,  $C_{\text{min}}^{\infty}$ , and  $C_{\text{av}}^{\infty}$  697
- Determination of Frequency of Drug Administration 698
- Determination of Both Dose and Dosage Interval 698
- Practice Problem 699
- Determination of Route of Administration 699
- Dosing Infants and Children 700
- Practice Problem 702
- Dosing the Elderly 702
- Practice Problems 703
- Clinical Example 704
- Dosing the Obese Patients 705
- Pharmacokinetics of Drug Interactions 706
- Inhibition of Drug Metabolism 710

Inhibition of Monoamine Oxidase (MAO) 712  
 Induction of Drug Metabolism 712  
 Inhibition of Drug Absorption 712  
 Inhibition of Biliary Excretion 713  
 Altered Renal Reabsorption Due to Changing  
   Urinary pH 713  
 Practical Focus 713  
 Effect of Food on Drug Disposition 713  
 Adverse Viral Drug Interactions 714  
 Population Pharmacokinetics 714  
 Clinical Example 722  
 Regional Pharmacokinetics 724  
 Chapter Summary 725  
 Learning Questions 725  
 Answers 728  
 References 731  
 Bibliography 732

### **23. Application of Pharmacokinetics to Specific Populations: Geriatric, Obese, and Pediatric Patients 735**

Specific and Special Populations 735  
 Module I: Application of Pharmacokinetics to the  
   Geriatric Patients 736  
 Summary 749  
 Learning Questions 749  
 Answers 750  
 References 751  
 Further Reading 754  
 Module II: Application of Pharmacokinetics to the  
   Obese Patients 754  
 Summary 760  
 Learning Questions 760  
 Answers 761  
 References 761  
 Module III: Application of Pharmacokinetics to the  
   Pediatric Patients 763  
 Summary 769  
 Learning Questions 770  
 Answers 771  
 References 773

### **24. Dose Adjustment in Renal and Hepatic Disease 775**

Renal Impairment 775  
 Pharmacokinetic Considerations 775

General Approaches for Dose Adjustment in Renal  
 Disease 777  
 Measurement of Glomerular Filtration Rate 779  
 Serum Creatinine Concentration and  
   Creatinine Clearance 780  
 Practice Problems 782  
 Dose Adjustment for Uremic Patients 785  
 Practice Problem 787  
 Practice Problem 792  
 Practice Problems 793  
 Practice Problem 795  
 Extracorporeal Removal of Drugs 796  
 Practice Problem 799  
 Clinical Examples 800  
 Effect of Hepatic Disease  
   on Pharmacokinetics 803  
 Practice Problem 805  
 Chapter Summary 809  
 Learning Questions 810  
 Answers 811  
 References 813  
 Bibliography 815

### **25. Empirical Models, Mechanistic Models, Statistical Moments, and Noncompartmental Analysis 817**

Empirical Models 818  
 Mechanistic Models 822  
 Noncompartmental Analysis 835  
 Comparison of Different Approaches 842  
 Selection of Pharmacokinetic Models 844  
 Chapter Summary 845  
 Learning Questions 845  
 Answers 846  
 References 847  
 Bibliography 848

### **Appendix A Applications of Software Packages in Pharmacokinetics 851**

### **Appendix B Glossary 875**

Index 879

# Contributors

S. Thomas Abraham, PhD  
Associate Professor  
Department of Pharmaceutical Sciences  
College of Pharmacy & Health Sciences  
Campbell University  
Buies Creek, North Carolina

Michael L. Adams, PharmD, PhD  
Associate Professor  
Department of Pharmaceutical Sciences  
College of Pharmacy & Health Sciences  
Campbell University  
Buies Creek, North Carolina

Antoine Al-Achi, PhD  
Associate Professor  
Campbell University  
College of Pharmacy & Health Sciences  
Buies Creek, North Carolina

Lily K. Cheung, PharmD  
Assistant Professor  
Department of Pharmacy Practice  
College of Pharmacy & Health Sciences  
Texas Southern University  
Houston, Texas

Diana Shu-Lian Chow, PhD  
Professor of Pharmaceutics  
Director  
Institute for Drug Education and Research (IDER)  
College of Pharmacy  
University of Houston  
Houston, Texas

Philippe Colucci, PhD  
Principal Scientist  
Learn and Confirm Inc.  
Sr. Laurent, QC, Canada

Dale P. Conner, Pharm.D.  
Director  
Office of Bioequivalence  
Office of Generic Drugs  
CDER, FDA  
Silver Spring, Maryland

Barbara M. Davit, PhD, JD  
Executive Director  
Biopharmaceutics  
Merck & Co.  
Kenilworth, New Jersey

Hong Ding, PhD  
Assistant Professor  
Department of Immunology  
Herbert Wertheim College of Medicine  
Florida International University  
Miami, Florida

John Z. Duan, PhD  
Master Reviewer  
Office of New Drug Products  
Office of Pharmaceutical Quality  
FDA/CDER  
Silver Spring, Maryland

Murray P. Ducharme, PharmD, FCCP, FCP  
President and CEO  
Learn and Confirm Inc.  
Sr. Laurent, QC, Canada  
Professeur Associé  
Faculté de Pharmacie  
University of Montreal, Canada  
Visiting Professor  
Faculty of Pharmacy  
Rhodes University, South Africa

Mathangi Gopalakrishnan, MS, PhD  
Research Assistant Professor  
Center for Translational Medicine  
School of Pharmacy  
University of Maryland  
Baltimore, Maryland

Phillip M. Gerk, PharmD, PhD  
Associate Professor  
Department of Pharmaceutics  
Virginia Commonwealth University  
MCV Campus  
School of Pharmacy  
Richmond, Virginia

Charles Herring, BSP Pharm, PharmD, BCPS, CPP  
Associate Professor  
Department of Pharmacy Practice  
College of Pharmacy & Health Sciences  
Campbell University  
Clinical Pharmacist Practitioner  
Adult Medicine Team  
Downtown Health Plaza of Wake Forest Baptist  
Health  
Winston-Salem, North Carolina

Christine Yuen-Yi Hon, PharmD, BCOP  
Clinical Pharmacology Reviewer  
Division of Clinical Pharmacology III  
Office of Clinical Pharmacology  
Office of Translational Sciences  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Silver Spring, Maryland

Minerva A. Hughes, PhD, RAC (US)  
Senior Pharmacologist  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Silver Spring, Maryland

Manish Issar, PhD  
Assistant Professor of Pharmacology  
College of Osteopathic Medicine of the Pacific  
Western University of Health Sciences  
Pomona, California

Vipul Kumar, PhD  
Senior Scientist I  
Nonclinical Development Department  
Cubist Pharmaceuticals Inc.  
Lexington, Massachusetts

S.W. Johnny Lau, RPh, PhD  
Senior Clinical Pharmacologist  
Food and Drug Administration  
Office of Clinical Pharmacology  
Silver Spring, Maryland

David S.H. Lee, PharmD, PhD  
Assistant Professor  
Department of Pharmacy Practice  
Oregon State University/Oregon Health and Science  
University College of Pharmacy  
Portland, Oregon

Patrick J Marroum, PhD  
Director  
Clinical Pharmacology and Pharmacometrics  
AbbVie  
North Chicago, Illinois

Shabnam N. Sani, PharmD, PhD  
Assistant Professor  
Department of Pharmaceutical and Administrative  
Sciences  
College of Pharmacy  
Western New England University  
Springfield, Massachusetts

Leon Shargel, PhD, RPh  
Manager and Founder  
Applied Biopharmaceutics, LLC  
Raleigh, North Carolina  
Affiliate Professor  
School of Pharmacy  
Virginia Commonwealth University  
Richmond, Virginia

Sandra Suarez Sharp, PhD  
Master Biopharmaceutics Reviewer/Biopharmaceutics  
Lead  
Office of New Drug Products/Division of  
Biopharmaceutics  
Office of Pharmaceutical Quality  
Food and Drug Administration  
Silver Spring, Maryland

Rodney Siwale, PhD, MS  
Assistant Professor  
Department of Pharmaceutical and Administrative  
Sciences  
College of Pharmacy  
Western New England University  
Springfield, Massachusetts

Changquan Calvin Sun, PhD  
Associate Professor of Pharmaceutics  
University of Minnesota  
Department of Pharmaceutics  
College of Pharmacy  
Minneapolis, Minnesota

He Sun, PhD  
President and CEO  
Tasly Pharmaceuticals Inc.  
Rockville, Maryland  
Professor and Chairman  
Department of Pharmaceutical Economics and Policy  
School of Pharmaceutical Science and Technology  
Tianjin University  
Tianjin, P. R. China

Vincent H. Tam, PharmD, BCPS (Infectious Diseases)  
Professor Department of Clinical Sciences and  
Administration  
University of Houston College of Pharmacy  
Texas Medical Center Campus  
Houston, Texas

Dr. Susanna Wu-Pong, PhD  
Associate Professor  
Director  
Pharmaceutical Sciences Graduate Program  
VCU School of Pharmacy  
Richmond, Virginia

Andrew B.C. Yu, PhD, RPh  
Registered Pharmacist  
Formerly senior reviewer, CDER, FDA  
Associate Pharmaceutics Professor  
Albany College of Pharmacy  
Albany, New York

Corinne Seng Yue, BPharm, MSc, PhD  
Principal Scientist  
Learn and Confirm Inc.  
Sr. Laurent, QC, Canada

Hong Zhao, PhD  
Clinical Pharmacology Master Reviewer  
Clinical Pharmacology Team Leader  
Office of Clinical Pharmacology (OCP)  
Office of Translational Sciences (OTS)  
Center for Drug Evaluation and Research (CDER)  
U.S. Food and Drug Administration (FDA)  
Silver Spring, Maryland

HaiAn Zheng, PhD  
Associate Professor  
Department of Pharmaceutical Sciences  
Albany College of Pharmacy and Health Sciences  
Albany, New York

*This page intentionally left blank*

# Preface

The publication of this seventh edition of *Applied Biopharmaceutics and Pharmacokinetics* represents over three decades in print. Since the introduction of classic pharmacokinetics in the first edition, the discipline has expanded and evolved greatly. The basic pharmacokinetic principles and biopharmaceutics now include pharmacogenetics, drug receptor theories, advances in membrane transports, and functional physiology. These advances are applied to the design of new active drug moieties, manufacture of novel drug products, and drug delivery systems. Biopharmaceutics and pharmacokinetics play a key role in the development of safer drug therapy in patients, allowing individualizing dosage regimens and improving therapeutic outcomes.

In planning for the seventh edition, we realized that we needed expertise for these areas. This seventh edition is our first edited textbook in which an expert with intimate knowledge and experience in the topic was selected as a contributor. We would like to acknowledge these experts for their precious time and effort. We are also grateful to our readers and colleagues for their helpful feedback and support throughout the years.

As editors of this edition, we kept the original objectives, starting with fundamentals followed by a holistic integrated approach that can be applied to practice (see scope and objectives in Preface to the first edition). This textbook provides the reader with a basic and practical understanding of the principles of biopharmaceutics and pharmacokinetics that can be applied to drug product development and drug therapy. Practice problems, clinical examples, frequently asked questions and learning questions are included in each chapter to demonstrate how these concepts relate to practical situations. This textbook remains unique

in teaching basic concepts that may be applied to understanding complex issues associated with *in vivo* drug delivery that are essential for safe and efficacious drug therapy.

The primary audience is pharmacy students enrolled in pharmaceutical science courses in pharmacokinetics and biopharmaceutics. This text fulfills course work offered in separate or combined courses in these subjects. Secondary audiences for this textbook are research, technological and development scientists in pharmaceutics, biopharmaceutics, and pharmacokinetics.

This edition represents many significant changes from previous editions.

- The book is an edited textbook with the collaboration of many experts well known in biopharmaceutics, drug disposition, drug delivery systems, manufacturing, clinical pharmacology, clinical trials, and regulatory science.
- Many chapters have been expanded and updated to reflect current knowledge and application of biopharmaceutics and pharmacokinetics. Many new topics and updates are listed in Chapter 1.
- Practical examples and questions are included to encourage students to apply the principles in patient care and drug consultation situations.
- Learning questions and answers appear at the end of each chapter.
- Three new chapters have been added to this edition including, *Biostatistics* which provides introduction for popular topics such as risk concept, non-inferiority, and superiority concept in new drug evaluation, and *Application of Pharmacokinetics in Specific Populations* which discusses issues such as drug and patient related pharmacy



topics in during therapy in various patient populations, and *Biopharmaceutic Aspects of the Active Pharmaceutical Ingredient and Pharmaceutical Equivalence* which explains the synthesis, quality and physical/chemical properties of the active pharmaceutical ingredients affect the

bioavailability of the drug from the drug product and clinical efficacy.

*Leon Shargel*  
*Andrew B.C. Yu*

# Preface to First Edition

The publication of the twelfth edition of this book is a testament to the vision and ideals of the original authors, Alfred Gilman and Louis Goodman, who, in 1941 set forth the principles that have guided the book through eleven editions: to correlate pharmacology with related medical sciences, to reinterpret the actions and uses of drugs in light of advances in medicine and the basic biomedical sciences, to emphasize the applications of pharmacodynamics to therapeutics, and to create a book that will be useful to students of pharmacology and to physicians. These precepts continue to guide the current edition.

As with editions since the second, expert scholars have contributed individual chapters. A multi-authored book of this sort grows by accretion, posing challenges editors but also offering memorable pearls to the reader. Thus, portions of prior editions persist in the current edition, and I hasten to acknowledge the contributions of previous editors and authors, many of whom will see text that looks familiar. However, this edition differs noticeably from its immediate predecessors. Fifty new scientists, including a number from out-side. the U.S., have joined as contributors, and all chapters have been extensively updated. The focus on basic principles continues, with new chapters on drug invention, molecular mechanisms of drug action, drug toxicity and poisoning, principles of antimicrobial therapy and pharmacotherapy of obstetrical and gynecological disorders. Figures are in full color. The editors have continued to standardize the organization of chapters: thus, students should easily find the basic physiology, biochemistry, and pharmacology set forth in regular type; bullet points highlight important lists within the text; the clinician and expert will find details in extract type under clear headings.

Online features now supplement the printed edition. The entire text, updates, reviews of newly approved drugs, animations of drug action, and hyper links to relevant text in the prior edition are available on the Goodman & Gilman section of McGraw-Hill's websites, *AccessMedicine.com* and *AccessPharmacy.com*. An Image Bank CD accompanies the book and makes all tables and figures available for use in presentations.

The process of editing brings into view many remarkable facts, theories, and realizations. Three stand out: the invention of new classes of drugs has slowed to a trickle; therapeutics has barely begun to capitalize on the information from the human genome project; and, the development of resistance to antimicrobial agents, mainly through their overuse in medicine and agriculture, threatens to return us to the pre-antibiotic era. We have the capacity and ingenuity to correct these shortcomings.

Many, in addition to the contributors, deserve thanks for their work on this edition; they are acknowledged on an accompanying page. In addition, I am grateful to Professors Bruce Chabner (Harvard Medical School/Massachusetts General Hospital) and Björn Knollmann (Vanderbilt University Medical School) for agreeing to be associate editors of this edition at a late date, necessitated by the death of my colleague and friend Keith Parker in late 2008. Keith and I worked together on the eleventh edition and on planning this edition. In anticipation of the editorial work ahead, Keith submitted his chapters before anyone else and just a few weeks before his death; thus, he is well represented in this volume, which we dedicate to his memory.

*Laurence L. Brunton*

# About the Authors

**Dr. Leon Shargel** is a consultant for the pharmaceutical industry in biopharmaceutics and pharmacokinetics. Dr. Shargel has over 35 years experience in both academia and the pharmaceutical industry. He has been a member or chair of numerous national committees involved in state formulary issues, biopharmaceutics and bioequivalence issues, institutional review boards, and a member of the USP Biopharmaceutics Expert Committee. Dr. Shargel received a BS in pharmacy from the University of Maryland and a PhD in pharmacology from the George Washington University Medical Center. He is a registered pharmacist and has over 150 publications including several leading textbooks in pharmacy. He is a member of various professional societies, including the American

Association Pharmaceutical Scientists (AAPS), American Pharmacists Association (APhA), and the American Society for Pharmacology and Experimental Therapeutics (ASPET).

**Dr. Andrew Yu** has over 30 years of experience in academia, government, and the pharmaceutical industry. Dr. Yu received a BS in pharmacy from Albany College of Pharmacy and a PhD in pharmacokinetics from the University of Connecticut. He is a registered pharmacist and has over 30 publications and a patent in novel drug delivery. He had lectured internationally on pharmaceuticals, drug disposition, and drug delivery.

# 1

# Introduction to Biopharmaceutics and Pharmacokinetics

Leon Shargel and Andrew B.C. Yu

## Chapter Objectives

- ▶ Define drug product performance and biopharmaceutics.
- ▶ Describe how biopharmaceutics affects drug product performance.
- ▶ Define pharmacokinetics and describe how pharmacokinetics is related to pharmacodynamics and drug toxicity.
- ▶ Define the term clinical pharmacokinetics and explain how clinical pharmacokinetics may be used to develop dosage regimens for drugs in patients.
- ▶ Define pharmacokinetic model and list the assumptions that are used in developing a pharmacokinetic model.
- ▶ Explain how the prescribing information or approved labeling for a drug helps the practitioner to recommend an appropriate dosage regimen for a patient.

## DRUG PRODUCT PERFORMANCE

---

Drugs are substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. Drugs are given in a variety of dosage forms or *drug products* such as solids (tablets, capsules), semisolids (ointments, creams), liquids, suspensions, emulsions, etc, for systemic or local therapeutic activity. Drug products can be considered to be drug delivery systems that release and deliver drug to the site of action such that they produce the desired therapeutic effect. In addition, drug products are designed specifically to meet the patient's needs including palatability, convenience, and safety.


*Drug product performance* is defined as the release of the drug substance from the drug product either for local drug action or for drug absorption into the plasma for systemic therapeutic activity. Advances in pharmaceutical technology and manufacturing have focused on developing quality drug products that are safer, more effective, and more convenient for the patient.

## BIOPHARMACEUTICS

---

*Biopharmaceutics* examines the interrelationship of the physical/chemical properties of the drug, the dosage form (drug product) in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption. The importance of the drug substance and the drug formulation on absorption, and *in vivo* distribution of the drug to the site of action, is described as a sequence of events that precede elicitation of a drug's therapeutic effect. A general scheme describing this dynamic relationship is illustrated in Fig. 1-1.

First, the drug in its dosage form is taken by the patient by an oral, intravenous, subcutaneous, transdermal, etc, route of administration. Next, the drug is released from the dosage form in a predictable and characterizable manner. Then, some fraction of the drug is absorbed from the site of administration into either the surrounding tissue for local action or into the body (as with oral dosage forms), or both. Finally, the drug reaches the site of action. A pharmacodynamic response results when the drug concentration at the site of



**FIGURE 1-1** Scheme demonstrating the dynamic relationship between the drug, the drug product, and the pharmacologic effect.

action reaches or exceeds the *minimum effective concentration* (MEC). The suggested dosing regimen, including starting dose, maintenance dose, dosage form, and dosing interval, is determined in clinical trials to provide the drug concentrations that are therapeutically effective in most patients. This sequence of events is profoundly affected—in fact, sometimes orchestrated—by the design of the dosage form and the physicochemical properties of the drug.

Historically, pharmaceutical scientists have evaluated the relative drug availability to the body *in vivo* after giving a drug product by different routes to an animal or human, and then comparing specific pharmacologic, clinical, or possible toxic responses. For example, a drug such as isoproterenol causes an increase in heart rate when given intravenously but has no observable effect on the heart when given orally at the same dose level. In addition, the *bioavailability* (a measure of systemic availability of a drug) may differ from one drug product to another containing the same drug, even for the same route of administration. This difference in drug bioavailability may be manifested by observing the difference in the therapeutic effectiveness of the drug products. Thus, the nature of the drug molecule, the route of delivery, and the formulation of the dosage form can determine whether an administered drug is therapeutically effective, is toxic, or has no apparent effect at all.

The US Food and Drug Administration (FDA) approves all drug products to be marketed in the United States. The pharmaceutical manufacturers must perform extensive research and development prior to approval. The manufacturer of a new drug product must submit a *New Drug Application* (NDA) to the FDA, whereas a generic drug pharmaceutical manufacturer must submit an *Abbreviated New Drug Application* (ANDA). Both the new and generic drug

product manufacturers must characterize their drug and drug product and demonstrate that the drug product performs appropriately before the products can become available to consumers in the United States.

Biopharmaceutics provides the scientific basis for drug product design and drug product development. Each step in the manufacturing process of a finished dosage form may potentially affect the release of the drug from the drug product and the availability of the drug at the site of action. The most important steps in the manufacturing process are termed *critical manufacturing variables*. Examples of biopharmaceutic considerations in drug product design are listed in Table 1-1. A detailed discussion of drug product design is found in Chapter 15. Knowledge of physiologic factors necessary for designing oral products is discussed in Chapter 14. Finally, drug product quality of drug substance (Chapter 17) and drug product testing is discussed in later chapters (18, 19, 20, and 21). It is important for a pharmacist to know that drug product selection from multisources could be confusing and needs a deep understanding of the testing procedures and manufacturing technology which is included in the chemistry, manufacturing, and control (CMC) of the product involved. The starting material (SM) used to make the API (active pharmaceutical ingredient), the processing method used during chemical synthesis, extraction, and the purification method can result in differences in the API that can then affect drug product performance (Chapter 17). Sometimes a by-product of the synthetic process, residual solvents, or impurities that remain may be harmful or may affect the product's physical or chemical stability. Increasingly, many drug sources are imported and the manufacturing of these products is regulated by codes or pharmacopeia in other countries. For example, drugs in Europe may be meeting EP (European Pharmacopeia) and since 2006,

**TABLE 1-1 Biopharmaceutic Considerations in Drug Product Design**

Items	Considerations
Therapeutic objective	Drug may be intended for rapid relief of symptoms, slow extended action given once per day, or longer for chronic use; some drug may be intended for local action or systemic action
Drug (active pharmaceutical ingredient, API)	Physical and chemical properties of API, including solubility, polymorphic form, particle size; impurities
Route of administration	Oral, topical, parenteral, transdermal, inhalation, etc
Drug dosage and dosage regimen	Large or small drug dose, frequency of doses, patient acceptance of drug product, patient compliance
Type of drug product	Orally disintegrating tablets, immediate release tablets, extended release tablets, transdermal, topical, parenteral, implant, etc
Excipients	Although very little pharmacodynamic activity, excipients may affect drug product performance including release of drug from drug product
Method of manufacture	Variables in manufacturing processes, including weighing accuracy, blending uniformity, release tests, and product sterility for parenterals

agreed uniform standards are harmonized in ICH guidances for Europe, Japan, and the United States. In the US, the USP-NF is the official compendia for drug quality standards.

Finally, the equipment used during manufacturing, processing, and packaging may alter important product attribute. Despite compliance with testing and regulatory guidance involved, the issues involving

pharmaceutical equivalence, bioavailability, bioequivalence, and therapeutic equivalence often evolved by necessity. The implications are important regarding availability of quality drug product, avoidance of shortages, and maintaining an affordable high-quality drug products. The principles and issues with regard to multisource drug products are discussed in subsequent chapters:

Chapter 14	Physiologic Factors Related to Drug Absorption	How stomach emptying, GI residence time, and gastric window affect drug absorption
Chapter 15	Biopharmaceutic Considerations in Drug Product Design	How particle size, crystal form, solubility, dissolution, and ionization affect <i>in vivo</i> dissolution and absorption. Modifications of a product with excipient with regard to immediate or delayed action are discussed. Dissolution test methods and relation to <i>in vivo</i> performance
Chapter 16	Drug Product Performance, <i>In Vivo</i> : Bioavailability and Bioequivalence	Bioavailability and bioequivalence terms and regulations, test methods, and analysis examples. Protocol design and statistical analysis. Reasons for poor bioavailability. Bioavailability reference, generic substitution. PE, PA, BA/BE, API, RLD, TE SUPAC (Scale-up postapproval changes) regarding drug products. What type of changes will result in changes in BA, TE, or performances of drug products from a scientific and regulatory viewpoint
Chapter 17	Biopharmaceutic Aspects of the Active Pharmaceutical Ingredient and Pharmaceutical Equivalence	Physicochemical differences of the drug, API due to manufacturing and synthetic pathway. How to select API from multiple sources while meeting PE (pharmaceutical equivalence) and TE (therapeutic equivalence) requirement as defined in CFR. Examples of some drug failing TE while apparently meeting API requirements. Formulation factors and manufacturing method affecting PE and TE. How particle size and crystal form affect solubility and dissolution. How pharmaceutical equivalence affects therapeutic equivalence. Pharmaceutical alternatives. How physicochemical characteristics of API lead to pharmaceutical inequivalency
Chapter 18	Impact of Drug Product Quality and Biopharmaceutics on Clinical Efficacy	Drug product quality and drug product performance Pharmaceutical development. Excipient effect on drug product performance. Quality control and quality assurance. Risk management Scale-up and postapproval changes (SUPAC) Product quality problems. Postmarketing surveillance

Thus, biopharmaceutics involves factors that influence (1) the design of the drug product, (2) stability of the drug within the drug product, (3) the manufacture of the drug product, (4) the release of the drug from the drug product, (5) the rate of dissolution/release of the drug at the absorption site, and (6) delivery of drug to the site of action, which may involve targeting the drug to a localized area (eg, colon for Crohn disease) for action or for systemic absorption of the drug.

Both the pharmacist and the pharmaceutical scientist must understand these complex relationships to objectively choose the most appropriate drug product for therapeutic success.

The study of biopharmaceutics is based on fundamental scientific principles and experimental methodology. Studies in biopharmaceutics use both *in vitro* and *in vivo* methods. *In vitro* methods are procedures employing test apparatus and equipment without involving laboratory animals or humans. *In vivo* methods are more complex studies involving human subjects or laboratory animals. Some of these methods will be discussed in Chapter 15. These methods must be able to assess the impact of the physical and chemical properties of the drug, drug stability, and large-scale production of the drug and drug product on the biologic performance of the drug.

## PHARMACOKINETICS

---

After a drug is released from its dosage form, the drug is absorbed into the surrounding tissue, the body, or both. The distribution through and elimination of the drug in the body varies for each patient but can be characterized using mathematical models and statistics. *Pharmacokinetics* is the science of the kinetics of drug absorption, distribution, and elimination (ie, metabolism and excretion). The description of drug distribution and elimination is often termed *drug disposition*. Characterization of drug disposition is an important prerequisite for determination or modification of dosing regimens for individuals and groups of patients.

The study of pharmacokinetics involves both experimental and theoretical approaches. The experimental aspect of pharmacokinetics involves the development of biologic sampling techniques,

analytical methods for the measurement of drugs and metabolites, and procedures that facilitate data collection and manipulation. The theoretical aspect of pharmacokinetics involves the development of pharmacokinetic models that predict drug disposition after drug administration. The application of statistics is an integral part of pharmacokinetic studies. Statistical methods are used for pharmacokinetic parameter estimation and data interpretation ultimately for the purpose of designing and predicting optimal dosing regimens for individuals or groups of patients. Statistical methods are applied to pharmacokinetic models to determine data error and structural model deviations. Mathematics and computer techniques form the theoretical basis of many pharmacokinetic methods. Classical pharmacokinetics is a study of theoretical models focusing mostly on model development and parameterization.

## PHARMACODYNAMICS

---

*Pharmacodynamics* is the study of the biochemical and physiological effects of drugs on the body; this includes the mechanisms of drug action and the relationship between drug concentration and effect. A typical example of pharmacodynamics is how a drug interacts quantitatively with a drug receptor to produce a response (effect). Receptors are the molecules that interact with specific drugs to produce a pharmacological effect in the body.

The pharmacodynamic effect, sometimes referred to as the pharmacologic effect, can be therapeutic and/or cause toxicity. Often drugs have multiple effects including the desired therapeutic response as well as unwanted side effects. For many drugs, the pharmacodynamic effect is dose/drug concentration related; the higher the dose, the higher drug concentrations in the body and the more intense the pharmacodynamic effect up to a maximum effect. It is desirable that side effects and/or toxicity of drugs occurs at higher drug concentrations than the drug concentrations needed for the therapeutic effect. Unfortunately, unwanted side effects often occur concurrently with the therapeutic doses. The relationship between pharmacodynamics and pharmacokinetics is discussed in Chapter 21.



## CLINICAL PHARMACOKINETICS

During the drug development process, large numbers of patients are enrolled in clinical trials to determine efficacy and optimum dosing regimens. Along with safety and efficacy data and other patient information, the FDA approves a label that becomes the package insert discussed in more detail later in this chapter. The approved labeling recommends the proper starting dosage regimens for the general patient population and may have additional recommendations for special populations of patients that need an adjusted dosage regimen (see Chapter 23). These recommended dosage regimens produce the desired pharmacologic response in the majority of the anticipated patient population. However, intra- and interindividual variations will frequently result in either a subtherapeutic (drug concentration below the MEC) or a toxic response (drug concentrations above the *minimum toxic concentration*, MTC), which may then require adjustment to the dosing regimen. *Clinical pharmacokinetics* is the application of pharmacokinetic methods to drug therapy in patient care. Clinical pharmacokinetics involves a multidisciplinary approach to individually optimized dosing strategies based on the patient's disease state and patient-specific considerations.

The study of clinical pharmacokinetics of drugs in disease states requires input from medical and pharmaceutical research. Table 1-2 is a list of 10 age adjusted rates of death from 10 leading causes of death in the United States in 2003. The influence of many diseases on drug disposition is not adequately studied. Age, gender, genetic, and ethnic differences can also result in pharmacokinetic differences that may affect the outcome of drug therapy (see Chapter 23). The study of pharmacokinetic differences of drugs in various population groups is termed *population pharmacokinetics* (Sheiner and Ludden, 1992; see Chapter 22). Application of Pharmacokinetics to Specific Populations, Chapter 23, will discuss many of the important pharmacokinetic considerations for dosing subjects due to age, weight, gender, renal, and hepatic disease differences. Despite advances in modeling and genetics, sometimes it is necessary to monitor the plasma drug concentration precisely in a patient for safety and multidrug dosing consideration. Clinical pharmacokinetics is also applied to

**TABLE 1-2 Ratio of Age-Adjusted Death Rates, by Male/Female Ratio from the 10 Leading Causes of Death\* in the US, 2003**

Disease	Rank	Male:Female
Disease of heart	1	1.5
Malignant neoplasms	2	1.5
Cerebrovascular diseases	3	4.0
Chronic lower respiration diseases	4	1.4
Accidents and others*	5	2.2
Diabetes mellitus	6	1.2
Pneumonia and influenza	7	1.4
Alzheimers	8	0.8
Nephrotis, nephrotic syndrome, and nephrosis	9	1.5
Septicemia	10	1.2

\*Death due to adverse effects suffered as defined by CDC.

Source: National Vital Statistics Report Vol. 52, No. 3, 2003.

*therapeutic drug monitoring* (TDM) for very potent drugs, such as those with a narrow therapeutic range, in order to optimize efficacy and to prevent any adverse toxicity. For these drugs, it is necessary to monitor the patient, either by monitoring plasma drug concentrations (eg, theophylline) or by monitoring a specific pharmacodynamic endpoint such as prothrombin clotting time (eg, warfarin). Pharmacokinetic and drug analysis services necessary for safe drug monitoring are generally provided by the *clinical pharmacokinetic service* (CPKS). Some drugs frequently monitored are the aminoglycosides and anti-convulsants. Other drugs closely monitored are those used in cancer chemotherapy, in order to minimize adverse side effects (Rodman and Evans, 1991).

### Labeling For Human Prescription Drug and Biological Products

In 2013, the FDA redesigned the format of the prescribing information necessary for safe and effective use of the drugs and biological products



(FDA Guidance for Industry, 2013). This design was developed to make information in prescription drug labeling easier for health care practitioners to access and read. The practitioner can use the prescribing information to make prescribing decisions. The labeling includes three sections:

- *Highlights of Prescribing Information (Highlights)*—contains selected information from the Full Prescribing Information (FPI) that health care practitioners most commonly reference and consider most important. In addition, highlights may contain any boxed warnings that give a concise summary of all of the risks described in the **Boxed Warning** section in the **FPI**.
- *Table of Contents (Contents)*—lists the sections and subsections of the FPI.
- *Full Prescribing Information (FPI)*—contains the detailed prescribing information necessary for safe and effective use of the drug.

An example of the Highlights of Prescribing Information and Table of Contents for Nexium (esomeprazole magnesium) delayed release capsules appears in Table 1-3B. The prescribing information sometimes referred to as the approved label or the package insert may be found at the FDA website, Drugs@FDA (<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/>). Prescribing information is updated periodically as new information becomes available. The prescribing information contained in the label recommends dosage regimens for the average patient from data obtained from clinical trials. The indications and usage section are those indications that the FDA has approved and that have been shown to be effective in clinical trials. On occasion, a practitioner may want to prescribe the drug to a patient drug for a non-approved use or indication. The pharmacist must decide if there is sufficient evidence for dispensing the drug for a non-approved use (off-label indication). The decision to dispense a drug for a non-approved indication may be difficult and often made with consultation of other health professionals.

## Clinical Pharmacology

*Pharmacology* is a science that generally deals with the study of drugs, including its mechanism, effects, and uses of drugs; broadly speaking, it includes

pharmacognosy, pharmacokinetics, pharmacodynamics, pharmacotherapeutics, and toxicology. The application of pharmacology in clinical medicine including clinical trial is referred to as clinical pharmacology. For pharmacists and health professionals, it is important to know that NDA drug labels report many important study information under **Clinical Pharmacology** in Section 12 of the standard prescription label (Tables 1-3A and 1-3B).

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

### 12.2 Pharmacodynamics

### 12.3 Pharmacokinetics

## Question

Where is toxicology information found in the prescription label for a new drug? Can I find out if a drug is mutagenic under side-effect sections?

## Answer

Nonclinical toxicology information is usefully in Section 13 under **Nonclinical Toxicology** if available. Mutagenic potential of a drug is usually reported under animal studies. It is unlikely that a drug with known humanly mutagenicity will be marketed, if so, it will be labeled with special warning. Black box warnings are usually used to give warnings to prescribers in Section 5 under Warnings and Precautions.

## Pharmacogenetics

Pharmacogenetics is the study of drug effect including distribution and disposition due to genetic differences, which can affect individual responses to drugs, both in terms of therapeutic effect and adverse effects. A related field is pharmacogenomics, which emphasizes different aspects of genetic effect on drug response. This important discipline is discussed in Chapter 13. Pharmacogenetics is the main reason why many new drugs still have to be further studied after regulatory approval, that is, postapproval phase 4 studies. The clinical trials prior to drug approval are generally limited such that some side effects and special responses due to genetic differences may not be adequately known and labeled.

**TABLE 1-3A Highlights of Prescribing Information for Nexium (Esomeprazole Magnesium) Delayed Release Capsules**

HIGHLIGHTS OF PRESCRIBING INFORMATION		
<p><b>These highlights do not include all the information needed to use NEXIUM safely and effectively. See full prescribing information for NEXIUM.</b></p> <p><b>NEXIUM (esomeprazole magnesium) delayed-release capsules, for oral use</b></p> <p><b>NEXIUM (esomeprazole magnesium) for delayed-release oral suspension</b></p> <p><b>Initial U.S. Approval: 1989 (omeprazole)</b></p>		
<p>..... <b>RECENT MAJOR CHANGES</b> .....</p>		
Warnings and Precautions. Interactions with Diagnostic Investigations for Neuroendocrine Tumors (5.8)		03/2014
<p>..... <b>INDICATIONS AND USAGE</b> .....</p>		
<p>NEXIUM is a proton pump inhibitor indicated for the following:</p> <ul style="list-style-type: none"> <li>• Treatment of gastroesophageal reflux disease (GERD) (1.1)</li> <li>• Risk reduction of NSAID-associated gastric ulcer (1.2)</li> <li>• <i>H. pylori</i> eradication to reduce the risk of duodenal ulcer recurrence (1.3)</li> <li>• Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (1.4)</li> </ul>		
<p>..... <b>DOSAGE AND ADMINISTRATION</b> .....</p>		
Indication	Dose	Frequency
<b>Gastroesophageal Reflux Disease (GERD)</b>		
Adults	20 mg or 40 mg	Once daily for 4 to 8 weeks
12 to 17 years	20 mg or 40 mg	Once daily for up to 8 weeks
1 to 11 years	10 mg or 20 mg	Once daily for up to 8 weeks
1 month to less than 1 year 2.5 mg, 5 mg or 10 mg (based on weight). Once daily, up to 6 weeks for erosive esophagitis (EE) due to acid-mediated GERD only.		
<b>Risk Reduction of NSAID-Associated Gastric Ulcer</b>		
	20 mg or 40 mg	Once daily for up to 6 months
<b><i>H. pylori</i> Eradication (Triple Therapy):</b>		
NEXIUM	40 mg	Once daily for 10 days
Amoxicillin	1000 mg	Twice daily for 10 days
Clarithromycin	500 mg	Twice daily for 10 days
<b>Pathological Hypersecretory Conditions</b>		
	40 mg	Twice daily
See full prescribing information for administration options (2)		
Patients with severe liver impairment do not exceed dose of 20 mg (2)		
<p>..... <b>DOSAGE FORMS AND STRENGTHS</b> .....</p> <ul style="list-style-type: none"> <li>• NEXIUM Delayed-Release Capsules: 20 mg and 40 mg (3)</li> <li>• NEXIUM for Delayed-Release Oral Suspension: 2.5 mg, 5 mg, 10 mg, 20 mg, and 40 mg (3)</li> </ul>		
<p>..... <b>CONTRAINDICATIONS</b> .....</p>		
Patients with known hypersensitivity to proton pump inhibitors (PPIs) (angioedema and anaphylaxis have occurred) (4)		

(Continued)

**TABLE 1-3A Highlights of Prescribing Information for Nexium (Esomeprazole Magnesium) Delayed Release Capsules (Continued)**

HIGHLIGHTS OF PRESCRIBING INFORMATION
<p style="text-align: center;"><b>WARNINGS AND PRECAUTIONS</b></p> <ul style="list-style-type: none"> <li>• Symptomatic response does not preclude the presence of gastric malignancy (5.1)</li> <li>• Atrophic gastritis has been noted with long-term omeprazole therapy (5.2)</li> <li>• PPI therapy may be associated with increased risk of <i>Clostridium difficile</i>-associated diarrhea (5.3)</li> <li>• Avoid concomitant use of NEXIUM with clopidogrel (5.4)</li> <li>• Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine (5.5)</li> <li>• Hypomagnesemia has been reported rarely with prolonged treatment with PPIs (5.6)</li> <li>• Avoid concomitant use of NEXIUM with St John's Wort or rifampin due to the potential reduction in esomeprazole levels (5.7,7.3)</li> <li>• Interactions with diagnostic investigations for Neuroendocrine Tumors: Increases in intragastric pH may result in hypergastrinemia and enterochromaffin-like cell hyperplasia and increased chromogranin A levels which may interfere with diagnostic investigations for neuroendocrine tumors (5.8,12.2)</li> </ul>
<p style="text-align: center;"><b>ADVERSE REACTIONS</b></p> <p>Most common adverse reactions (6.1):</p> <ul style="list-style-type: none"> <li>• Adults (≥18 years) (incidence ≥1%) are headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth</li> <li>• Pediatric (1 to 17 years) (incidence ≥2%) are headache, diarrhea, abdominal pain, nausea, and somnolence</li> <li>• Pediatric (1 month to less than 1 year) (incidence 1%) are abdominal pain, regurgitation, tachypnea, and increased ALT</li> </ul> <p><b>To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</b></p>
<p style="text-align: center;"><b>DRUG INTERACTIONS</b></p> <ul style="list-style-type: none"> <li>• May affect plasma levels of antiretroviral drugs – use with atazanavir and nelfinavir is not recommended: if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction (7.1)</li> <li>• May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, and digoxin) Patients treated with NEXIUM and digoxin may need to be monitored for digoxin toxicity. (7.2)</li> <li>• Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels (7.3)</li> <li>• Clopidogrel: NEXIUM decreases exposure to the active metabolite of clopidogrel (7.3)</li> <li>• May increase systemic exposure of cilostazol and an active metabolite. Consider dose reduction (7.3)</li> <li>• Tacrolimus: NEXIUM may increase serum levels of tacrolimus (7.5)</li> <li>• Methotrexate: NEXIUM may increase serum levels of methotrexate (7.7)</li> </ul>
<p style="text-align: center;"><b>USE IN SPECIFIC POPULATIONS</b></p> <ul style="list-style-type: none"> <li>• Pregnancy: Based on animal data, may cause fetal harm (8.1)</li> </ul> <p><b>See 17 for PATIENT COUNSELING INFORMATION and FDA-approved Medication Guide.</b></p>

Revised: 03/2014

## PRACTICAL FOCUS

### Relationship of Drug Concentrations to Drug Response

The initiation of drug therapy starts with the manufacturer's recommended dosage regimen that includes the drug dose and frequency of doses (eg, 100 mg every 8 hours). Due to individual differences in the patient's genetic makeup (see Chapter 13 on

pharmacogenetics) or pharmacokinetics, the recommended dosage regimen drug may not provide the desired therapeutic outcome. The measurement of plasma drug concentrations can confirm whether the drug dose was subtherapeutic due to the patient's individual pharmacokinetic profile (observed by low plasma drug concentrations) or was not responsive to drug therapy due to genetic difference in receptor response. In this case, the drug concentrations

**TABLE 1-3B Contents for Full Prescribing Information for Nexium (Esomeprazole Magnesium) Delayed Release Capsules**

FULL PRESCRIBING INFORMATION: CONTENTS*	
<b>1. INDICATIONS AND USAGE</b>	
1.1	Treatment of Gastroesophageal Reflux Disease (GERD)
1.2	Risk Reduction of NSAID-Associated Gastric Ulcer
1.3	<i>H. pylori</i> Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
1.4	Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
<b>2. DOSAGE AND ADMINISTRATION</b>	
<b>3. DOSAGE FORMS AND STRENGTHS</b>	
<b>4. CONTRAINDICATIONS</b>	
<b>5. WARNINGS AND PRECAUTIONS</b>	
5.1	Concurrent Gastric Malignancy
5.2	Atrophic Gastritis
5.3	<i>Clostridium difficile</i> associated diarrhea
5.4	Interaction with Clopidogrel
5.5	Bone Fracture
5.6	Hypomagnesemia
5.7	Concomitant Use of NEXIUM with St John's Wort or rifampin
5.8	Interactions with Diagnostic Investigations for Neuroendocrine Tumors
5.9	Concomitant Use of NEXIUM with Methotrexate
<b>6. ADVERSE REACTIONS</b>	
6.1	Clinical Trials Experience
6.2	Postmarketing Experience
<b>7. DRUG INTERACTIONS</b>	
7.1	Interference with Antiretroviral Therapy
7.2	Drugs for Which Gastric pH Can Affect Bioavailability
7.3	Effects on Hepatic Metabolism/Cytochrome P-450 Pathways
7.4	Interactions with Investigations of Neuroendocrine Tumors
7.5	Tacrolimus
7.6	Combination Therapy with Clarithromycin
7.7	Methotrexate
<b>8. USE IN SPECIFIC POPULATIONS</b>	
8.1	Pregnancy
8.3	Nursing Mothers
8.4	Pediatric Use
8.5	Geriatric Use
<b>10. OVERDOSAGE</b>	
<b>11. DESCRIPTION</b>	
<b>12. CLINICAL PHARMACOLOGY</b>	
12.1	Mechanism of Action
12.2	Pharmacodynamics
12.3	Pharmacokinetics
12.4	Microbiology
<b>13. NONCLINICAL TOXICOLOGY</b>	
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2	Animal Toxicology and/or Pharmacology
<b>14. CLINICAL STUDIES</b>	
14.1	Healing of Erosive Esophagitis
14.2	Symptomatic Gastroesophageal Reflux Disease (GERD)
14.3	Pediatric Gastroesophageal Reflux Disease (GERD)
14.4	Risk Reduction of NSAID-Associated Gastric Ulcer
14.5	<i>Helicobacter pylori</i> ( <i>H. Pylon</i> ) Eradication in Patients with Duodenal Ulcer Disease
14.6	Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
<b>16. HOW SUPPLIED/STORAGE AND HANDLING</b>	
<b>17. PATIENT COUNSELING INFORMATION</b>	

\*Sections or subsections omitted from the full prescribing information are not listed.

Source: FDA Guidance for Industry (February 2013).